A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Stephan Miehlke  ¹     Christoph Schlag  ²     Ulrike von Arnim  ³     Javier Molina-Infante  ⁴     Christoph Schmöcker  ⁵     Albert Jan Bredenoord  ⁶     Constanza Ciriza De Los Ríos  ⁷     Stefan Schubert  ⁸     Ahmed Madisch  ⁹     Jamal Hayat  ¹⁰     Jan Tack  ¹¹     Ralph Mueller  ¹²     Roland Greinwald  ¹²     Alex Straumann  ¹³     Alfredo J. Lucendo  ¹⁴     Stefan Brueckner  ¹⁵     Stephen E. Attwood  ¹⁶     Alain M. Schoepfer  ^17    
1 Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany
² Klinikum rechts der Isar - TU München, München, Germany
³ University Hospital Magdeburg, Madgeburg, Germany
⁴ Hospital San Pedro de Alcantara, Caceres, Spain
⁵ Sana Klinikum Lichtenberg, Berlin, Germany
⁶ Academisch Med. Centrum Amsterdam, Amsterdam, Netherlands
⁷ Hospital 12 de Octubre, Madrid, Spain
⁸ Gastroenterologist in Private Practice, Berlin, Germany
⁹ CRH Clinic Hannover, Hannover, Germany
¹⁰ St. George`s University Hospitals NHS Trust, London, United Kingdom
¹¹ University Hospital Leuven, Leuven, Belgium
¹² Dr. Falk Pharma GmbH, Freiburg, Germany
¹³ Swiss EoE Research Network, Olten, Switzerland
¹⁴ Hospital General de Tomelloso, Tomelloso, Spain
¹⁵ Universitätsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany
¹⁶ Durham University, North Tyneside, United Kingdom
¹⁷ University Hospital (CHUV), Lausanne, Switzerland

Topic
Immunology, Oesophagus, Paediatrics

Session
Eosinophilic oesophagitis: The essential

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)